Status:
UNKNOWN
Copenhagen Prospective Personalized Oncology (CoPPO)
Lead Sponsor:
Ulrik Lassen
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with advanced solid tumors referred to the Phase 1 Unit are offered mapping of GA for identification of pts who could benefit from a personalized treatment.
Detailed Description
Two ultrasound-guided biopsies obtained to be stored in RNAlater® for DNA and RNA purification. A 3rd biopsy for histology is paraffin embedded. SNP-array (Affymetrix Cytoscan HD) from DNA (tumor) is ...
Eligibility Criteria
Inclusion
- Solid tumor
- No standard treatment option
- PS 0-1
- Lesion assessable for biopsy
- Measurable disease
- Informed consent
Exclusion
- Life expectancy \< 3 months
- Bone marrow suppression
- Abnormal renal or hepatic function
- Serious concurrent medical conditions
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT02290522
Start Date
May 1 2013
End Date
December 1 2023
Last Update
October 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark